Posts Tagged payers

Sex Reassignment Surgery For Transgenders: Should It Be Covered By Health Insurance?

transgender_flag_thmbPeople who identify themselves as transgender evolved in their belief of a gender-assignment mistake when they are self-aware of stereotypes involving genders, which can occur as early as the age of three years old. This sense of identity can adversely affect their self-esteem to the point that they believe the only avenue to improve is to partake in a transition process so their physiological gender coincides with their internal identity belief. Transitioning from one gender to another is a process that can be mentally exhausting, emotionally charged and prohibitively expensive.

What makes transitioning genders so financially draining? Studies on this issue have identified discrimination and lack of health insurance to be the two primary obstacles.

  • Discrimination. Transgender people often have trouble finding health care providers that are trained in and respectful of their concerns. Their self-identity may also resulting more difficulty finding high-paying jobs despite their skill set, since their concerns are unique and very few companies have the resources to address them properly.
  • Lack of Insurance Coverage. Health insurance companies are reluctant to foot the costs of transitioning, which has many phases, such as hormone therapy to actual gender reassignment surgery. As it is not a quick process, the cost of changing gender can be prohibitive for insurance companies as well as the insured. This makes such a process less common than it might otherwise be for some people.

Doctorwithsyringeinhandsandflagonbackgroundseries-LGBTpeopleHere are some examples of costs associated with gender reassignment.  Hormone therapy typically costs USD 100 a month and surgery can be on average USD 25,000 to USD 30,000. Phalloplasties, the surgery that female to male transgenders go through in order to fully transition, are most expensive, with this surgery typically costing more than USD 100,000, according to the Transgender Law Center.

Should insurance companies consider covering gender re-assignment?  Johns Hopkins University Bloomberg’s School of Public Health and UCLA’s William’s Institute of Law has examined this issue, and offer data that might make insurers consider the financial benefits of expanded coverage, which will also be beneficial to those undergoing such reassignment.

The study, published in the Journal of General Internal Medicine, explored the cost-effectiveness of transgender health-care coverage for insurance companies, especially when compared with long-term treatments such as chronic ailments for which there are no cures.  Lead author William Padula has pointed out significant arguments in favor of covering transition.

pullout_oneA primary argument in favor of providing coverage for gender transition is the one-time cost for transitioning, which includes surgery and ongoing hormone-replacement therapy. The study of 34 employers which include transgender coverage in their work-related health plans revealed that the majority of costs incurred by employees was quite low (at most 1 percent of total health-care expenditures). With this coverage, there seemed to be a noted absence of employee healthcare utilization, but even of those employers who reported costs associated with gender transition, the actual impact on companies over a multi-year period was insignificant.Williams-Institute-Logo

The survey, conducted by the Williams Institute, focused on employers that provided transition-related health care coverage to its employees. Results suggest that it is in favor for both employees and employers without any significant financial impact on the company.

  • Low costs. According to the survey, two-thirds of employer-participants reported there is no additional cost in providing this additional coverage for their employees.

 

  • Few claims. If an employee claims any transition-related health care benefits, it might financially impact their employer. The survey grouped the participants according to the number of employees and the claims the latter has made for transitioning. According to them, it’s just 0.054 claimants per 1,000

 

  • Limited options. Despite this, most of these employer-covered transition treatments have restrictions which limit the options of transgender people from accessing it. Only 59 percent of the participants cover surgical procedures and 48 percent limit their coverage within the United States.

There is hope for transgender transition. Medicare and Medicaid services have begun paying for sexual reassignment pullout_twosurgeries and other transition-related care, but only on a case-by-case basis as deemed “medically necessary”by consulting professionals in each situation. It is estimated that 0.3 percent (or 3 in 1,000) of U.S. adults are self-identified as transgender, and neary 50 million people are currently enrolled in Medicare.

Some U.S. companies have initiated inclusion of these benefits for their employees. This change has resulted in a rise in sexual-reassignment surgeries paid by insurance. This may be a financial advantage for those who are looking forward to transitioning, but with increased access  due to affordability, the previous six-month wait may extend to a year or more as more and more patients get in line to externally display their internal gender identity.

The transgender population is small, but has become much more visible in recent years in political, medical, social and civil areas of life. Gender transition has been a high hill to climb for many transgender people due to the prohibitive cash cost. However, the Williams Institute survey gives new hope to transgender people individually, but also sheds light on the benefits of offering transgender care in health-insurance plans. As a result, employers are embracing very low costs in adding the coverage to their group plans while seeing a dramatic increase in social consciousness and promoting diversity and equality in their workforces. In a cost-benefit analysis, providing gender-reassignment coverage seems to only be a positive net effect across the board.

 

Reference:

  1. Leal, S. (2015). I Can’t Afford to Transition: The Unseen Costs of Being Transgender in 2015. Marie Claire. Retrieved 18 August 2016, from http://www.marieclaire.com/culture/news/a15164/transgender-operation-procedure-costs/
  2. Desmon, S. (2015). Insurance for sex reassignments is cost effective – Futurity. Futurity. Retrieved 18 August 2016, from http://www.futurity.org/transgender-insurance-1063212-2/
  3. Epic Week For Transgender Rights Expands With Health Care Protections — ThinkProgress. (2016). Medium. Retrieved 18 August 2016, from https://thinkprogress.org/epic-week-for-transgender-rights-expands-with-health-care-protections-e355d3d51d6b#.axwrtsofo
  4. Green, J. & Tracer, Z. (2016). Sex Reassignment Is Latest Company Benefit in Equality Push – Bloomberg. Bloomberg.com. Retrieved 18 August 2016, from http://www.bloomberg.com/news/articles/2015-09-21/sex-reassignment-is-latest-company-benefit-in-push-for-equality
  5. Herman, PhD, J. (2013). Costs and Benefits of Providing Transition-Related Health Care Coverage In Employee Health Benefits Plans. Williams Institute Law (UCLA). Retrieved 18 August 2016, from http://williamsinstitute.law.ucla.edu/wp-content/uploads/Herman-Cost-Benefit-of-Trans-Health-Benefits-Sept-2013.pdf

 

Author Bio

halland_chenHalland Chen is an MD who currently practices at a Vein and Pain Centers of America headquartered in New York City. With a passion in regenerative medicine, Dr. Halland helps patients alleviate pain and avoiding surgery by allowing patients to heal naturally using the body’s own growth factors and repair mechanisms. He is on the Board of Directors for the American Academy of Regenerative Medicine, whose leadership Directors also come from the Harvard Stem Cell Group and Mayo Clinic. Among his other passions, Dr. Halland travels alongside with tech entrepreneurs across various locations internationally to cultivate new upcoming and emerging technologies, kite-surfing, and writing informative articles to help educate readers.

, , , ,

No Comments

Paying for Specialty Pharmaceuticals: The Case of Injectable Oncology Drugs

John Schneider

John Schneider, Ph.D

According to the American Cancer Society, the financial costs of cancer are high for both the person with cancer and for society as a whole. The National Institutes of Health (NIH) estimated the 2009 overall annual costs of cancer in the U.S. to be $216.6 billion, consisting of $86.6 billion in direct costs and $130 billion in indirect mortality costs attributable to cancer. This year, about 585,720 U.S. residents are expected to die of cancer. Cancer is the second most common cause of death in the U.S., surpassed only by heart disease. Cancer accounts for nearly 1 out of every 4 deaths in the United States.

A large proportion of cancer-attributable costs are directly related to treatment.  While there is clear value to many new drugs in general [1-3] and cancer drugs in particular [4, 5], in recent years there has been growing concern about the overall costs of cancer treatment, and the proportion of health care budgets allocated to oncology care.[6-8]

A large part of oncology treatment costs are referred to as “injectables.” Provider-infused or injected chemotherapy represents the largest portion of medical benefit injectable costs at about 38% of the total costs.[9]  Including chemotherapy support drugs, such as antiemetics, injectable drugs associated with cancer care represent 55% of allowed medical injectable costs [9].

The portion of total provider-administered injectable expenditures attributable to cancer has been relatively steady in recent years, but the costs of other oncology support drugs have been increasing.  Provider-administered injectables used to treat rheumatologic disorders represent the second largest therapeutic area by expenditures (6% of total medical injectable costs in 2011).

Cancer treatment cost control continues to be a major goal of managed care organizations.  Similar to trends overall in U.S. pharmaceutical payment methods, one payer survey reported that 63% of commercial payers employ formularies for injectable and infusible drugs for at least some therapeutic classes.[9]  Both small and large payers had equal probability of having a formulary. However, only 55% of payers report that health care providers typically adhere to formulary policy.

For the typical payer, seven therapeutic classes currently have a medical formulary in place.[9]  As of 2012, the vast majority of payers employed formularies in the following therapeutic classes: erythropoiesis-stimulating agents (99%); intravenous immune globulin (97%); chemotherapy-induced nausea and vomiting (CINV) (97%); colony-stimulating agents (96%); hemophilia (93%); biologic response modifiers (100%); and chemotherapy (97%).  Within these therapeutic classes, there is a clear trend toward establishing formularies.  From 2011 to 2012, intravenous immune globulin increased by 8%, chemotherapy-induced nausea and vomiting increased by 20%, colony-stimulating agents by 20%, hemophilia by 19%, biologic response modifiers by 36%, and chemotherapy by 40%.

Payers identified seven cancer types as being under formulary management from 2010 to 2013 [9].  Although there were large increases in formulary use from 2010 to 2013 for metastatic breast cancer and prostate cancer, there was a sizable drop in use of formularies for treatments for non-small cell lung cancer.  The increase in the portion of lives under formulary for metastatic breast cancer is probably because of the FDA change in the Avastin label, and the increase in the prostate cancer is likely due to the approval of Provenge.

Li et al. (2013) conducted a survey to assess the extent of hospital outpatient oncology drug management, management strategies employed, and specific drugs/tumor types of most concern for inappropriate use and cost.[10] Most institutions (99%) reported using at least one form of control to manage outpatient oncology drug therapy; 89% establish preferred therapies, and most use a multidisciplinary management team consisting of oncologists, pharmacists, nurses, and other practitioners.

There has also been growing concern on the payer side over the steady rise in the overall costs of oncology drugs and oncology support drugs.  These concerns have prompted discussions over reforming oncology payment on the part of public and private payers.[4, 5, 11-15]  For example, on the private payer side, United Healthcare (UHC) launched a pilot program aimed to reduce spending on oncology drugs.  The program is a bundled, or “episode-of-care”, payment for treatments, which is based on the actual cost of drugs plus a case management fee.[5, 16]  The aim of the program is to reduce errors and incentives for physicians to administer unnecessary drug treatment.  Payments under UHC work as follows: as opposed to reimbursing drugs at the average sales price plus an extra 6%, the insurer pays an amount much closer to the actual cost of the drug, plus an administrative fee.  These types of programs and efforts on the part of payers will continue to evolve over the next few years, thereby compelling oncology drug makers to make more convincing arguments for the value of their treatments.[17]

What challenges are you experiencing in the oncology drug and oncology support drug arena, as either a payer, provider, pharma company, or patient?

-John Schneider, PhD, Cara Scheibling & Zack Mower

Avalon Health Economics

http://www.avalonecon.com

 

 

 

References

 

  1. Berndt, E.R., International Comparisons of Pharmeceutical Prices: What Do We Know, and What Does It Mean? Journal of Health Economics, 2000. 19(2): p. 283-87.
  2. Lichtenberg, F., Pharmaceutical Innovation, Mortality Reduction, and Economic Growth, in Measuring the Gains from Medical Research: An Economic Approach, K.M. Murphy and R.H. Topel, Editors. 2003, University of Chicago Press: Chicago. p. 74-109.
  3. Lichtenberg, F.R., Are the Benefits of Newer Drugs Worth Their Cost? Evidence From the 1996 MEPS. Health Affairs, 2001. 20(5): p. 241-251.
  4. Danzon, P.M. and E. Taylor, Drug pricing and value in oncology. Oncologist, 2010. 15 Suppl 1: p. 24-31.
  5. Robinson, J.C., Value and payment for oncology in the United States. Ann Pharm Fr, 2013. 71(5): p. 285-90.
  6. Kelly, R.J. and T.J. Smith, Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol, 2014.
  7. Meropol, N.J., et al., American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol, 2009. 27(23): p. 3868-74.
  8. Sullivan, R., et al., Delivering affordable cancer care in high-income countries. Lancet Oncol, 2011. 12(10): p. 933-80.
  9. Johnson, K.A., Medical Pharmacy & Oncology Trend Report: 2012 (Third Edition), 2012, Magellan Pharmacy Solutions/ICORE HEALTHCARE.
  10. Li, E., R. Schleif, and B. Edelen, Hospital management of outpatient oncology treatment decisions: a survey to identify strategies and concerns. J Oncol Pract, 2013. 9(5): p. e248-54.
  11. Danielson, E., J. Demartino, and J.A. Mullen, Managed care & medical oncology: the focus is on value. J Natl Compr Canc Netw, 2010. 8 Suppl 7: p. S28-37.
  12. Mullins, C.D., R. Montgomery, and S. Tunis, Uncertainty in assessing value of oncology treatments. Oncologist, 2010. 15 Suppl 1: p. 58-64.
  13. Smith, T.J. and B.E. Hillner, Concrete options and ideas for increasing value in oncology care: the view from one trench. Oncologist, 2010. 15 Suppl 1: p. 65-72.
  14. Colla, C.H., et al., Impact of payment reform on chemotherapy at the end of life. J Oncol Pract, 2012. 8(3 Suppl): p. e6s-e13s.
  15. Bach, P.B., Reforming the payment system for medical oncology. JAMA, 2013. 310(3): p. 261-2.
  16. Goozner, M., United Healthcare, Five Oncology Practices Try Bundled Payments. JNCI, 2011. 103(1).
  17. Robinson, J.C. and S. Howell, Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use. Health Aff (Millwood), 2014. 33(10): p. 1745-50.

 

, , , , , ,

No Comments